Grassley Urges Administration to Fix Misclassification of EpiPen, Other Drugs Under Medicaid Drug Rebate Program - Insurance News | InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home Now reading Newswires
Topics
    • Advisor News
    • Annuity Index
    • Annuity News
    • Companies
    • Earnings
    • Fiduciary
    • From the Field: Expert Insights
    • Health/Employee Benefits
    • Insurance & Financial Fraud
    • INN Magazine
    • Insiders Only
    • Life Insurance News
    • Newswires
    • Property and Casualty
    • Regulation News
    • Sponsored Articles
    • Washington Wire
    • Videos
    • ———
    • About
    • Meet our Editorial Staff
    • Advertise
    • Contact
    • Newsletters
  • Exclusives
  • NewsWires
  • Magazine
  • Newsletters
Sign in or register to be an INNsider.
  • AdvisorNews
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Exclusives
  • INN Magazine
  • Insurtech
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Video
  • Washington Wire
  • Life Insurance
  • Annuities
  • Advisor
  • Health/Benefits
  • Property & Casualty
  • Insurtech
  • About
  • Advertise
  • Contact
  • Editorial Staff

Get Social

  • Facebook
  • X
  • LinkedIn
Newswires
Newswires RSS Get our newsletter
Order Prints
June 16, 2017 Newswires
Share
Share
Post
Email

Grassley Urges Administration to Fix Misclassification of EpiPen, Other Drugs Under Medicaid Drug Rebate Program

Congressional Documents & Publications

For months, Sen. Chuck Grassley has pressed for the accurate classification of prescription drugs under the Medicaid Drug Rebate Program. Grassley's work was prompted by the news that EpiPen maker Mylan was in discussions with the Justice Department to settle a case and repay the taxpayers for over-charging for EpiPen. The Department of Health and Human Services Office of Inspector General most recently told Grassley that the taxpayers may have overpaid for EpiPen by as much as $1.27 billion from 2006 through 2016, far more than previously discussed. Grassley also is seeking accurate overpayment amounts for Dilaudid and Prilosec, two other popular drugs that reportedly were misclassified. Grassley made the following comment on the news that the White House is working on an executive order to address the high cost of prescription drugs.

"I'm very interested in the executive order. The Administration is right to focus on the high cost of prescription drugs. The sticker shock is real. It affects people paying out of pocket, and it affects spending by Medicaid and Medicare. One step the Administration could and should take immediately is to make sure all prescription drugs are classified the right way under the Medicaid Drug Rebate Program. Billions of dollars owed to the taxpayers are at stake. We're all worried about health care spending and trying to get the most bang for the buck. Holding prescription drug companies accountable for their obligations to taxpayers is a good place to start. It's unclear why the previous administration apparently let Mylan get by for years with over-charging for EpiPens, and apparently other companies with their drugs, but there's a chance now to fix that mistake. The current administration should do it."

Grassley's letter to then-President-elect Trump urging appropriate classification under the Medicaid Drug Rebate Program is available here http://www.grassley.senate.gov/sites/default/files/constituents/2016-12-12%20CEG%20to%20Trump%20%28Drug%20Pricing%20and%20Competition%29.pdf. Grassley's January letter to the outgoing administration on the issue is available here https://www.grassley.senate.gov/sites/default/files/constituents/2017-01-04%20CEG%20to%20CMS%20%28Drug%20Misclassifications%29..pdf. His Oct. 3 letter to the prior administration on the EpiPen misclassification is available here http://www.grassley.senate.gov/sites/default/files/constituents/2016-10-03%20CEG%20to%20CMS%20%28EpiPen%20Misclassification%29.pdf.

Read this original document at: https://www.grassley.senate.gov/news/news-releases/grassley-urges-administration-fix-misclassification-epipen-other-drugs-under

Older

HHS Secretary Price To Durbin: I Have Not Seen Senate Republicans’ Plan To Repeal Health Care

Newer

ISAKSON HIGHLIGHTS CHOICE, APPEALS REFORMS AS CRITICAL VA PRIORITIES

Advisor News

  • Survey: Most Americans still feel prosperous despite economic worries
  • SEC settlement would require Tai Lopez, two others, to pay $6.8 million
  • The Gen Z money paradox
  • NAIFA applauds final SECURE 2.0 regulations
  • What will Democrats in Congress do about healthcare and retirement?
More Advisor News

Annuity News

  • Best’s Market Segment Report: AM Best Maintains Stable Outlook on US Life/Annuity Insurance Segment
  • AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
  • Boomers want retirement protection, but their actions don’t match their mindset
  • NAIC task force to address LTC riders
  • ‘It’s really shocking:’ Regulators scrutinize assets backing annuity sellers
More Annuity News

Health/Employee Benefits News

  • States push short-term insurance as healthcare costs climb
  • WYDEN, SANDERS, SENATE DEMOCRATS CALL OUT INSURANCE COMPANY COLLUSION WITH TRUMP ADMINISTRATION TO KICK THOUSANDS OF AMERICANS OFF HEALTH INSURANCE
  • WYDEN STATEMENT ON FINANCE COMMITTEE DEMOCRATIC MAJORITY AGENDA
  • Health insurance switch costs city
  • New LTC solutions fill a critical gap for clients
More Health/Employee Benefits News

Life Insurance News

  • AM Best Upgrades Credit Ratings of CTBC Insurance Company Ltd
  • AM Best Affirms Credit Ratings of NongHyup Property and Casualty Insurance Company Limited
  • AM Best Affirms Credit Ratings of Delphi Financial Group, Inc. and Its Subsidiaries; Upgrades Issuer Credit Rating of Standard Security Life Insurance Company of New York
  • November Issue of Best’s Review Ranks US Life Reinsurers and More
  • Nebraska widow’s big win against life insurer in legal limbo
More Life Insurance News

NEWS INSIDE

  • Companies
  • Earnings
  • Economic News
  • INN Magazine
  • Insurtech News
  • Newswires Feed
  • Regulation News
  • Washington Wire
  • Videos

FEATURED OFFERS

Press Releases

  • OpenRoad Insurance Data Shows 40% of Collector Vehicles Are Model Year 1980 or Newer
  • Insurvoice Lets Independent Insurance Agency Owners Analyze Every Customer Call in ChatGPT or Claude
  • Spectrum Weather & Specialty Insurance Celebrates 15 Years and Welcomes the Next Generation
  • Royal Neighbors of America® Increases Service Capacity
  • Benefits Studio Launches to Fill the Missing Middle of Benefits Navigation at $49/mo
More Press Releases > Add Your Press Release >

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

Topics

  • Advisor News
  • Annuity Index
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • From the Field: Expert Insights
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Magazine
  • Insiders Only
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Washington Wire
  • Videos
  • ———
  • About
  • Meet our Editorial Staff
  • Advertise
  • Contact
  • Newsletters

Top Sections

  • AdvisorNews
  • Annuity News
  • Health/Employee Benefits News
  • InsuranceNewsNet Magazine
  • Life Insurance News
  • Property and Casualty News
  • Washington Wire

Our Company

  • About
  • Advertise
  • Contact
  • Meet our Editorial Staff
  • Magazine Subscription
  • Write for INN

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2026 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • InsuranceNewsNet Magazine

Sign in with your Insider Pro Account

Not registered? Become an Insider Pro.